Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously tre...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Thorac Oncol
Hoofdauteurs: Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://ncbi.nlm.nih.gov/pubmed/30316010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.10.003
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items